Literature DB >> 7525569

Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding.

M M Rosenkilde1, M Cahir, U Gether, S A Hjorth, T W Schwartz.   

Abstract

Mutational analysis of the NK-1 receptor indicates that residues involved in non-peptide antagonist binding cluster around the outer portion of transmembrane segments (TM) V and VI. In contrast mutations affecting the binding of the natural peptide agonist, substance P, are scattered in the exterior part of the receptor. Recently it was reported that a number of mutations in TM-II also seriously impair substance P binding. Here we confirm that Ala substitutions for these residues located on a hydrophilic helical face of TM-II basically eliminate substance P binding to the NK-1 receptor, provided that a radiolabeled non-peptide antagonist is used as radioligand. Surprisingly, radiolabeled substance P bound well to all these mutant receptors and was displaced with only slightly reduced affinity by the unlabeled peptide and by the non-peptide antagonists. The wild-type homologous NK-2 receptor displayed properties similar to those observed in the mutated NK-1 receptors, i.e. concomitant high affinity binding of radiolabeled agonist peptide (in this case neurokinin A), yet low affinity, G-protein independent competition of unlabeled peptide with radiolabeled non-peptide antagonist. It is concluded that substitutions in TM-II of the NK-1 receptor do not affect the high affinity binding of substance P but instead block the ability of the peptides to compete for non-peptide antagonist binding. It is suggested that certain mutations can impair interchange between receptor conformations that each bind different ligands with high affinity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525569

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Conserved polar residues in the transmembrane domain of the human tachykinin NK2 receptor: functional roles and structural implications.

Authors:  D Donnelly; S Maudsley; J P Gent; R N Moser; C R Hurrell; J B Findlay
Journal:  Biochem J       Date:  1999-04-01       Impact factor: 3.857

2.  Molecular requirements for inhibition of the chemokine receptor CCR8--probe-dependent allosteric interactions.

Authors:  P C Rummel; K N Arfelt; L Baumann; T J Jenkins; S Thiele; H R Lüttichau; A Johnsen; J Pease; S Ghosh; R Kolbeck; M M Rosenkilde
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

3.  Allosteric and orthosteric sites in CC chemokine receptor (CCR5), a chimeric receptor approach.

Authors:  Stefanie Thiele; Anne Steen; Pia C Jensen; Jacek Mokrosinski; Thomas M Frimurer; Mette M Rosenkilde
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

4.  Molecular Architecture of G Protein-Coupled Receptors.

Authors:  A Michiel van Rhee; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  1996-01-01       Impact factor: 4.360

Review 5.  Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family.

Authors:  J Peter; H Burbach; R A Adan; S J Lolait; F W van Leeuwen; E Mezey; M Palkovits; C Barberis
Journal:  Cell Mol Neurobiol       Date:  1995-10       Impact factor: 5.046

6.  Reversed binding of a small molecule ligand in homologous chemokine receptors - differential role of extracellular loop 2.

Authors:  P C Jensen; S Thiele; A Steen; A Elder; R Kolbeck; S Ghosh; T M Frimurer; M M Rosenkilde
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

7.  Genetic transfer of a nonpeptide antagonist binding site to a previously unresponsive angiotensin receptor.

Authors:  H Ji; W Zheng; Y Zhang; K J Catt; K Sandberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

Review 8.  Perspective: Implications of Ligand-Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors.

Authors:  Wijnand J C van der Velden; Laura H Heitman; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-18

9.  CoMFA analyses of C-2 position salvinorin A analogs at the kappa-opioid receptor provides insights into epimer selectivity.

Authors:  Donna L McGovern; Philip D Mosier; Bryan L Roth; Richard B Westkaemper
Journal:  J Mol Graph Model       Date:  2010-01-04       Impact factor: 2.518

10.  Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis.

Authors:  S Thiele; J Mungalpara; A Steen; M M Rosenkilde; J Våbenø
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.